Loading
Natural Alternatives International Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by LEDOUX MARK A, was filed 06 Mar 2026.
Natural Alternatives International Inc: what insiders have been doing
Natural Alternatives International Inc, founded in 1980, is a Healthcare & Pharma company based in San Marcos, United States. Its directors and officers file their transactions with SEC (Form 4). Between 22 October 2025 and 22 October 2026, 6 insiders published 24 filings.
The flow runs one way only: 1 insider bought (14 purchases totalling €23k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 chief executive. One trade stands out by size: a purchase of €5,477 from Ledoux Mark A, disclosed on 20 February 2026.
For context, the typical company on the same exchange (median of 3,171 companies) published 24 filings over the same period, against 24 filings here. Over the whole record (from 2016), the tally stands at 14 purchases and 61 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 June 2026), the company reported revenue of 142.5 m USD and net income of -20.7 m USD.
The latest purchase dates back some time: it was published 231 days ago, on 6 March 2026. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
215
Thresholds
n/a
Buy Volume
€22,764
14 ops. · all time
Sell Volume
€8M
61 ops. · all time
Who traded when
BuySaleMark A. Ledoux14 buys
Since the insiders bought
- -11.0%Entry US$2.81 · Close at T+90 US$2.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,583 of 26,248 companies
28.9
score / 100
Value48
Quality10
FCF yld32%
Earn yld-187%
EV/EBITDA·
ROE-35%
Gross mgn7.2%
Net mgn-10%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
US$1.16
Analyst consensus
Income statement
RevenueUS$129.9M
Gross profitUS$9.3M7% margin
EBITDA-US$5.3M-4% margin
Net income-US$13.6M-14.5% margin
Valuation
P/Book0.1x
Beta0.35
Balance sheet & cash
Market capUS$7.3M
Total debtUS$59M
Free Cash FlowUS$2.3M
Debt / Equity100%
Profitability & ownership
ROE-35.0%
ROA-3.7%
% insiders21.4%
% institutions36.4%
Last declaration on 10 March 2026
Declarations215 total
20,000 shares0Common StockSEC:0001437749-26-007618:1
15,000 shares0Common StockSEC:0001437749-26-007620:1
12,000 shares0Common StockSEC:0001437749-26-007619:1
8,000 shares0Common StockSEC:0001437749-26-007515:0
5,151 shares@ US$2.73100.0% of flowCommon StockSEC:0001437749-26-007620:0
4,308 shares@ US$2.73100.0% of flowCommon StockSEC:0001437749-26-007619:0
3,484 shares@ US$2.733.0% of flowCommon StockSEC:0001437749-26-007618:0
8,000 shares0Common StockSEC:0001437749-26-007514:0
8,000 shares0Common StockSEC:0001437749-26-007513:0
218 shares@ US$2.750.0% of flowCommon StockSEC:0001437749-26-007255:1
Canonical exit: 3 Jun 2026 (T+90)
532 shares@ US$2.800.1% of flowCommon StockSEC:0001437749-26-007255:2
Canonical exit: 4 Jun 2026 (T+90)
500 shares@ US$2.770.4% of flowCommon StockSEC:0001437749-26-007255:0
Canonical exit: 2 Jun 2026 (T+90)
500 shares@ US$2.790.1% of flowCommon StockSEC:0001437749-26-006754:1
Canonical exit: 31 May 2026 (T+90)
500 shares@ US$2.850.4% of flowCommon StockSEC:0001437749-26-006754:0
Canonical exit: 28 May 2026 (T+90)
500 shares@ US$2.850.1% of flowCommon StockSEC:0001437749-26-006139:1
Canonical exit: 27 May 2026 (T+90)
250 shares@ US$2.800.0% of flowCommon StockSEC:0001437749-26-006139:2
Canonical exit: 28 May 2026 (T+90)
500 shares@ US$2.810.4% of flowCommon StockSEC:0001437749-26-006139:0
Canonical exit: 26 May 2026 (T+90)
750 shares@ US$2.700.1% of flowCommon StockSEC:0001437749-26-005423:1
Canonical exit: 24 May 2026 (T+90)
1,000 shares@ US$2.710.1% of flowCommon StockSEC:0001437749-26-005423:2
Canonical exit: 25 May 2026 (T+90)
250 shares@ US$2.6550.2% of flowCommon StockSEC:0001437749-26-005423:0
Canonical exit: 21 May 2026 (T+90)
500 shares@ US$2.560.0% of flowCommon StockSEC:0001437749-26-004935:1
Canonical exit: 19 May 2026 (T+90)
1,500 shares@ US$2.560.1% of flowCommon StockSEC:0001437749-26-004935:2
Canonical exit: 20 May 2026 (T+90)
2,500 shares@ US$2.5962.0% of flowCommon StockSEC:0001437749-26-004935:0
Canonical exit: 18 May 2026 (T+90)
10,000 sharesCommon StockSEC:0001437749-26-000287:0
7,559 shares@ US$3.83543.0% of flowCommon StockSEC:0001437749-25-007059:0
25 of 215 declarations
About Natural Alternatives International Inc
Natural Alternatives International, Inc. (NAII) is a U.S.-listed company trading on the Nasdaq market in the United States. Founded in 1980 by Mark LeDoux, the business is headquartered in Carlsbad, California, and has long operated with a bi-national footprint that includes manufacturing capabilities in California and Switzerland. NAII is best understood as a specialized nutrition-platform company rather than a mass-market consumer brand: it serves third-party clients that need formulation, manufacturing, and commercialization support for customized nutritional products.
The company’s core activity is private-label and contract manufacturing of vitamins, minerals, herbal products, and other dietary supplements. Its service stack goes beyond toll manufacturing and includes custom formulation, clinical study support, regulatory compliance, international product registration, label-law support, packaging design, scientific research, and marketing assistance. This integrated offering is important competitively because many customers in the nutrition industry want a single partner that can move a product from concept to shelf while managing quality, compliance, and localization across jurisdictions.
Read moreShow less
NAII has also built brand and intellectual-property exposure around CarnoSyn®, its beta-alanine ingredient platform. That ingredient has been central to the company’s sports-nutrition positioning and has been extended into adjacent wellness and healthy-aging applications over time. Historically, the company has invested in product and technology development around beta-alanine delivery formats, including instant-release and sustained-release versions. For investors, that matters because proprietary ingredients can support differentiation, customer stickiness, and licensing or branded-input economics, even when overall contract-manufacturing margins remain under pressure.
From a competitive standpoint, NAII occupies a niche in the fragmented nutritional-supplement manufacturing market. Its strengths are science-led formulation, regulatory know-how, and a long operating history; its challenges are typical of the sector, including customer concentration, pricing pressure, raw-material volatility, and the need to maintain quality and compliance across production facilities. The company’s geographic presence in the United States and Switzerland gives it a platform for serving domestic and international clients, which is especially relevant for customers seeking global market access.
For SEO and investor context, it is also worth noting that NAII is followed by the market as a small-cap company, which can mean higher share-price sensitivity to earnings releases, contract wins or losses, and insider activity disclosed through SEC Form 4 filings. In February 2026, the company reported fiscal second-quarter results showing net sales of $34.8 million and a net loss of $2.6 million. That recent update reinforces NAII’s profile as an execution-driven niche supplier in the health and nutrition chain, with a business model tied to customized supplement demand, proprietary ingredient value, and regulatory credibility in the United States and abroad.
